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Abstract
Chemotherapy drugs are generally cytotoxic and can causemajor side effects, including vomiting/
nausea, fatigue, hair loss and pain. The use of targeted nanostructures to deliver drugs directly to
tumours has the potential to reduce the side effects by decreasing the exposure of healthy cells and
reducing the amount of drug needed. DNA can be used as a structuralmaterial to build drug-
delivering nanorobots, but questions remain over the practicality of this approach.Here we show that
it is potentially feasible forDNAnanostructure drug delivery to bemore cost-effective than the drug-
only approach.Our result suggests that the barriers to the development ofDNAnanostructure-based
drug delivery are likely to be primarily technical, regulatory and ethical rather than financial, as the
potential exists for this to be a profitable therapeutic approach.
Background
In one study, 45% of chemotherapy patients ques-
tioned said that the side effects of chemotherapy
affected their lives ‘much’ or ‘very much’ [1]. In
another study, 86% of patients reported at least one
side effect, and 27% reported a severe side effect [2]. In
principle, using nanostructures (of size 1–100 nm) to
deliver drugs to particular cells could allow tumours to
be targeted specifically [3], reducing toxicity and side
effects. Nanostructures tend to accumulate preferen-
tially in tumours rather than ‘normal’ tissue, but the
extent and mechanism are currently under debate [4].
Cancer cells can also be targeted actively [5], where
nanostructures are modified with ligands or antibo-
dies, enabling them to interact with particular biomar-
kers in the tumour. Some nanotherapeutics can self-
deploy in response to changes characteristic of the
tumour microenvironment, or be steered using exter-
nal stimuli including magnetic fields, light, heat and
ultrasound.
To date, use of nanomedicines has been limited, in
part due to regulatory challenges. However, a few
nanostructure-based chemotherapeutics have been
approved for clinical use [6], the first being pegylated
liposomal doxorubicin (PLD), which was approved in
1994 and is also known as Doxil, Caelyx or Lipodox
[7]. Here, the well-established anti-cancer drug doxor-
ubicin is encapsulated in a liposome, which is coated
with PEG (Polyethylene glycol) to render it hydro-
philic and reduce the chance that it will be removed
rapidly by the body [8]. Pegylated liposomal doxor-
ubicin is significantly less toxic than free doxorubicin,
and survives much longer, giving time for the drug to
accumulate in the tumour. However, liposomal dox-
orubicin has not supplanted free doxorubicin. The
drug paclitaxel is also available in a nanotechnology-
enabled formulation, as albumin-bound nano-
particles, and in Scotland this has been deemed to be a
cost-effective monotherapy for metastatic breast can-
cerwhen anthracyclines are not to be used [9].
The principles of DNA nanotechnology [10] can
be used to assemble drug delivery vehicles [11]. DNA
nanostructures aremade from synthetic DNA strands,
the sequences of which are designed to ensure the
nanostructure assembles into the desired configura-
tion, through themechanism of base-pairing. The ear-
liest structure to be made was a DNA cube [12],
followed by other cage-like polyhedra [13, 14]. Larger
nanostructures are commonly assembled using the
technique of DNA origami [15], which can produce
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a long single-stranded DNA ‘scaffold’ into a designed
shape by hybridizing it with many short single-stran-
ded DNA oligonucleotides (‘staples’), which are
designed to bind to specific domains [17]. An alter-
native technique is based on DNA configurations
defined by a polyhedralmesh [18, 19].
DNA nanotherapeutics [20] show potential due to
their biocompatibility and customizable morphology.
Some chemotherapy agents can be loaded by inter-
calation between the base pairs, and the nanostructure
is expected to accumulate in the tumour as a matter of
course. The DNA nanostructure shape can affect the
release characteristics of intercalating drugs [21], and
not all potential intercalation sites are accessible for
binding [22]. Doxorubicin-laden DNA nanos-
tructures can be cytotoxic to resistant cancer cells that
are not killed by free doxorubicin [23], and genes can
be delivered with the drugs for combination therapy
[24]. For active targeting, DNA origami nanorobots
[25] can be loaded with therapeutic cargos such as
thrombin [26] by specific modification of component
strands, with the nanorobot being guided to the
tumour by active targeting, using a recognition mech-
anismbased onmolecules such as aptamers.
When DNA nanostructures are used as drug deliv-
ery vehicles, cells are exposed to a large number of
synthetic DNA sequences, and it is conceivable that
this could have a significant effect, as the structure
could potentially contain a complicated set of genetic
instructions. Hence, it is usual to perform control
experiments in which the cells are treated with a solu-
tion of nanostructures that contain zero chemother-
apy agent or have been otherwise inactivated.
Normally, such structures have minimal or no effect
on the target cells [23–26]. However, p53 genes
attached to the edge of a DNA origami nanostructure
can have a significant effect on cell viability and this
has been proposed as a gene therapy technique [24]
Presumably, the information encoded in the con-
stituent sequences of a compact nanostructure is rela-
tively inaccessible, compared to the instructions found
in an unencumbered DNA oligonucleotide tethered to
the edge of such an object. Alternatively, it is possible
that the quasi-random sequences in the nanos-
tructures are meaningless, unlike the p53 gene. As the
technology of DNA nanostructure-based drug deliv-
ery develops further, these two possibilities must be
explored in detail, to ensure that potential off-target
effects of the therapy can be identified. Interestingly, it
has been shown that plain DNA nanostructures (with-
out any drug at all) can alleviate symptoms of acute
kidney injury in mice [27], but this was attributed to
scavenging of reactive oxygen species rather than any
genetic effect.
As evidenced above, many papers have been pub-
lished on technical aspects of DNA nanostructure-
based drug delivery. However, to the best of our
knowledge no-one has yet published an economic
assessment of the concept, despite the fact that
increasing attention is being given to patenting DNA
nanotechnology inventions and commercializing
them [28]. The aim of this work is to ascertain whether
DNA nanostructures are likely to be a cost-effective
means of delivering chemotherapy drugs. At present,
very limited information is available about the safety
and efficacy of DNA-nanostructure-enabled treat-
ments. Some experiments have been carried out in cell
culture [21, 23, 25], and a few animal studies have been
performed [24, 26]. However, to the best of our
knowledge, no human studies have been conducted.
No DNA nanostructure-based clinical trials are listed
on the World Health Organization’s International
Clinical Trials Registry Platform (https://apps.who.
int/trialsearch/), which includes data fromAmerican,
EU and Chinese databases, among others. However,
even at this early stage, it is important to evaluate the
potential cost-effectiveness to establish potential for
translation and value to industry. The problem must
be framed such that a meaningful answer can be
obtained despite the gaps in our information, which
requires abstract assumptions.
In this study, we establish benchmarks for the per-
formance of a DNA nanostructure-based therapy in
comparison with the equivalent therapy without
nanostructures, assuming that the use of DNA nanos-
tructures enhances quality of life and/or provides
more years of life without changing the amount of
drug used. We also consider a scenario in which the
nanostructures reduce the quantity of drug needed.
We do not explicitly consider technical or regulatory
viability, and we focus exclusively on costs. We note
that our method could also be applied to the assess-
ment of other early-stage technologies where informa-
tion is limited. We use the concept of a quality-
adjusted life year (QALY), which is used inter-
nationally to assess cost-effectiveness of new health-
care interventions, by appraising the performance of a
new intervention in comparison with the status quo,
ideally before the newmeasure is introduced [29].
The number of QALYs gained upon the introduc-
tion of a new treatment is defined as the product of the
quality of life [30] and the number of additional years
of life, where quality of life is defined by an assessment
of wellbeing, based on a questionnaire. One year of
perfect health is equivalent to one QALY. Treatments
are often described as cost-effective if the cost per
additional QALY gained lies below a given threshold,
which varies depending on the healthcare system.
Values quoted include £20–30 k for NICE (the
National Institute for Health and Care Excellence,
which approves the use of medicines within the Eng-
lish healthcare system) [30]. The same figure is used by
the Scottish Medicines Consortium [31], and $50k is
often used in other parts of the world [32]. QALYs are
not the only factor considered by healthcare providers
when they decide which interventions to deploy [32].
Some countries do not use QALYs, and particular
challenges in the use ofQALYs for evaluation of cancer
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treatments include fluctuations in the quality of life,
switching between therapies and the lack of data on
overall survival rates [33]. However, QALYs are still
used frequently to assess cost-effectiveness of cancer
drugs. For example, in one study pazopanib was com-
pared to sunitinib for metastatic renal cell carcinoma,
within the United Kingdom [34]. Overall, it was found




We examined the company reports of 13 selected
pharmaceutical companies, representing many of the
larger players in the sector. From each report, we
extracted the figure described as ‘net earnings’, ‘net
profit’, ‘net income’, or equivalent. We also extracted
the ‘total revenue’, ‘total sales’, ‘sales’, ‘revenue’ or
‘turnover’ where available. In some reports, only the
‘net revenue’ or ‘net sales’ figure was given. We
expressed the net profit as a percentage of the revenue
figure we had extracted, and obtained values ranging
from 7.7% to 35.3%, with an average of 17.8%. In our
model, we therefore assumed a range of profit margin
p from 0.05 (i.e. 5%) to 0.40. This covers all the values
obtained for the companies we examined. We present
full details of our analysis in supplementary data 1,
which is available online at stacks.iop.org/BPEX/6/
065030/mmedia.
Manufacturing cost forDNAorigami, cm,DNA
Traditionally, DNA origami is prepared using the
M13mp18 bacteriophage genome as a scaffold. This
can be acquired commercially; for instance tilibit
nanosystems offers 800 picomoles of single-stranded
DNAwith this sequence for €635 (approximately £530
at exchange rate of €1=£0.83, 14th December 2019).
New England Biolabs provides 10 μg (4.2 pmol) for
£32 (excl. VAT), excluding any institutional discounts.
The staples are usually bought in the form of synthetic
oligonucleotides in plates. Based on prices from a
representative DNA synthesis company (Integrated
DNA Technologies, again excluding institutional dis-
counts and VAT) the price of a full set of staples,
containing a total of 7249 nucleotides, at 25 nmole
synthesis scale is £1300 (IDT: £0.18/base for 15–60
base oligos). 1 mg of DNA origami contains approxi-
mately 210 pmol of folded nanostructures. At a five-
fold excess of staples, this means that 1050 pmol of
staples are required, representing a fraction of 1.05/25
of the full set made, representing a cost of approxi-
mately £55. The corresponding quantity of scaffold
from tilibit would cost approximately £139. Hence,
with this approach the price of the raw materials to
make 1 mg of DNA origami would be nearly £200.
However, in a recent paper Praetorius et al estimated
that their biotechnological approach could reduce the
cost of DNA origami to as little as €0.18 per mg for
production at scale, including labour and overheads
[35]. In our model we assume for most calculations a
fixed DNA origami manufacture cost cm,DNA equal to
this value (£0.15 with exchange rate as at 14th
December 2019).
Mass of drug needed,mdrug, and cost of drug, cdrug
Themass of drug needed is highly variable, depending
on the drug, the patient and whether the drug is being
used as a monotherapy or in combination with other
treatments. In order to estimate the range of possible
parameters, we considered 6 particular case studies of
‘conventional’ chemotherapy treatments. We selected
the case studies to include examples of different drug
types e.g. taxanes, anthracyclines and an antimetabo-
lite. We considered mainly monotherapies, but also
included a combination therapy based on paclitaxel
and a platinum-containing compound. Where possi-
ble, we focused on drugs that are used for the most
common types of cancer, which are identified in
officialUK statistics as breast, lung, prostate, colorectal
[36, 37]. To calculate the mass and cost of drug, we
combined information from official NICE (National
Institute for Health and Care Excellence) ‘evidence-
based recommendations’, entries in the British
National Formulary (also known as MedicinesCom-
plete) [38] and dosage suggestions on the electronic
Medicines Compendium [39]. Dosage is often given in
terms of mg per body surface area, which varies from
patient to patient. We assumed an average value of
body surface area of 1.79 m2, as given in [40]. Full
details of our case studies are given in supplementary
data 2. In clinical practice, treatment and dosage
should always be determined by a qualified specialist
in oncology and chemotherapy.
In the six case studies, the cumulative mass of che-
motherapy drugs used per treatment ranged over
more than three orders of magnitude, from 251mg to
313 g (note units). However, the highest figure was an
outlier, and if this is omitted, the values range from
251mg to 2.7 g, differing by about one order ofmagni-
tude. The cost permg ranged from less than a penny to
£19.09. The cheapest price corresponded to the drug
forwhich the anomalously high quantity was required,
and when this was omitted the next lowest cost was
£1.26/mg. For our model we therefore assumed a
range of mdrug from 0.1 g to 3 g, and drug costs from
£0.50 to £20 permg.
Mass ratio, r
To establish the range of possible values for mass ratio
we considered the results of several different studies.
In the seminal paper on targeted delivery of cargo to
specific cells, Douglas et al [25] attached fluorescently
labelled antibody fragments to a DNA origami nanor-
obot. The origami structure comprised 7308 base
pairs, with an approximate molecular weight of
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4.8 MDa, while the mass of the antibody fragment was
approximately 55 kDa. On average, there were three
antibody fragments per nanorobot, which gives a total
mass of 165 kDa of antibody for 4.5MDa ofDNA and a
mass ratio of 0.165/4.5 or 3.4%.
Some drugs are loaded into DNA nanostructures
by intercalation between DNA bases. An early study of
DNA origami examined the effect of ethidium bro-
mide intercalation on origami structure [41] and we
can use the results of that study to estimate the mass
loading ratio for the case of ethidium bromide (EtBr).
It was found that the most heavily loaded structure
contained 53 EtBr intercalations per helix, with 191
base-pairs per helix. Hence, there were 53/191 EtBr
molecules per base pair. The molar mass of EtBr is
394.3 Da and hence the mass loading ratio is
(53×394.3)/(191×650), which is approximately
17%.
A recent study of the interactions between fluor-
escent intercalator YOYO-1 and DNA origami tiles
suggested that there were 67±25 YOYO molecules
per tile [22]. Assuming that the tile contained 6480 bp,
and that the molecular weight of YOYO-1 is 1271 Da,
this gives a mass loading ratio of 67×1.271/
4200=2%. In another study, an origami nanos-
tructure was loaded with daunorubicin [42], which
also intercalates between base pairs, it was observed
that the treatment strategy was effective when there
were 0.46 to 1 daunorubicin molecules per base pair.
When the structure was overloaded (more than one
molecule per base pair), aggregation and efficacy
decline were observed. Given a daunorubicin mole-
cular weight of 527.5 Da and an average base pair
molecular weight of 650 Da, this gives a mass loading
ratio of between 37%and 81%.
Wemay also consider the drug doxorubicin (Dox),
which is similar to daunorubicin. Dox is used in
numerous chemotherapy regimes (supplementary
information, treatment case study 2) and it is a popular
choice for DNA nanostructure drug delivery studies
because it is fluorescent and readily available. How-
ever, as noted by Keller and Linko [43] and Ijäs et al
[44], spectroscopic studies of Dox can yield peculiar or
ambiguous results. Some studies have reported results
suggesting extremely high drug loading, with multiple
Dox molecules per base pair, giving mass loading
ratios as high as 721% (for 8.6 Dox/bp) [24] or even
6448% (for 78 Dox/bp) [23] (details given in supple-
mentary calculation 1). AsDox is an intercalator, steric
considerations imply that this is impossible. Even a 1:1
Dox/base pair ratio is somewhat implausible, because
this would be likely to induce significant disruption to
the structure, but this value can be used as an upper
limit. At a 1:1 ratio, the mass loading ratio would be
84%.Other studies have reported lower loading ratios.
For instance, Raniolo et al loadedDNA octahedra with
Dox and obtained a mass loading ratio of approxi-
mately 10% [45] (supplementary calculation 1). More
recently, Ijäs et al obtained results that indicated a typi-
cal mass loading ratio of approximately 27% for Dox-
loaded origami structures [44].
In the studies that we considered, excluding the
implausible results, mass loading ratios ranged from
2% to just over 80%. Hence, in our model we used a
range of 1% to 100%.
Total cost of R&D for new therapy,ΔCr&d
One estimate placed the cost of developing a new drug
at $2.87bn (in 2013 dollars), when the costs of
unsuccessful projects and post-approval R&D were
included [46]. However, for the scenarios considered
in this paper, the active agent is already known and the
delivery method is changed. Clinical trials would still
be required, and the cost of such trials can be hundreds
of millions of dollars [47]. We therefore consider a
range of development costs, from £50million to
£4billion.
Number of treatments per year, t
Our analysis of pharmaceutical company reports
confirmed that their annual revenues were often tens
of billions of dollars. It is therefore reasonable to
assume that a single therapy could yield annual income
of $100M. An average cost per treatment of around
$2000 would be consistent with our analysis of the
prices of various therapies (supplementary data 1).
This suggests that the typical number of treatments
could be around ($100M/$2000)=50 000. In our
model we consider a range of number of treatments
per year, from 10 000 to 200 000. The number of
treatments will vary depending on the incidence of the
disease being treated and relative efficacy of the
treatment, among other factors.
Time to recoup cost, y
While a patent can theoretically protect a new drug for
20 years, in practice, the patent is likely to be filed at an
early stage of the process, and a significant proportion
of the patent lifetime will then be taken up with
development and approval. Hence, it is desirable for
costs to be recouped as quickly as possible. In ourmodel
we assume that the costswill be recouped in 1–8 years.
Range and spacing of parameters
For the purposes of our study, we evaluated the range
of parameters shown in table 1.We used evenly spaced
test values for all parameters, specified using the
MATLAB command linspace. For example, we
specified the possible values for m (mg of drug per
treatment) with the command m=linspace
(100,3000,x), where x=20. This yielded the
following range of values form, rounded to the nearest
whole number for the purposes of presentation here:
(100, 253, 405, 558, 711, 863, 1016, 1168, 1321, 1474,
4
Biomed. Phys. Eng. Express 6 (2020) 065030 E LColeridge andKEDunn
1626, 1779, 1932, 2084, 2237, 2389, 2542, 2695,
2847, 3000)
We applied similar statements for the other para-
meters, and tested every possible combination of the
values defined in this way. This means that our model
assumed no correlation between the parameters listed in
table 1, andwe treated themas independent variables. It is
conceivable that some of these parameters could be cou-
pled i.e. dependent on each other. For instance, the mass
of drug required (m) and themass loading ratio (r) could
be affected by the underlying chemistry of the drug and
mode of action and therefore might be related. There
could also be a connection between the profit margin (p),
the development cost (ΔCr&d), the number of years (y) to
recoup the cost and thenumber of treatments per year (t),
depending on the business model of the manufacturer.
Furthermore, the acceptable cost per QALY (CQ) and the
number of treatments per year (t) could be connected, as
it might be deemed acceptable to increase the threshold
cost for a particularly rare but devastating type of cancer.
At this time, it is not possible toquantify potential correla-
tions such as those noted in this paragraph and we there-
fore omitted them from the model. In this way, we
investigated the broadest possible range of scenarios, and
our model can be applied to more specific situations in
the future, when these are fully defined by experimental
andclinical studies.
Results
Total cost of treatments with andwithout
nanostructures
Let the cost to a health service of treatment i be CT,i . If
the profit of the manufacturer is ignored, this cost is
the sum of the manufacture cost, CM, (including
labour and ‘parts’), a share, CD, of the development
costs, and the cost of administering the treatment, CA
(including the cost of personnel, hospital visits etc).
Hence the cost in a break-even scenario is:
= + +-C C C CT ibreak even M i D i A i, , , ,
The actual cost will include an ‘acceptable’ profit
for the manufacturer. Let the manufacturer’s net
profit margin be p, defined as net profit divided by rev-
enue. The profit applies to themanufacture and devel-
opment costs incurred by themanufacturer. Hence:
= + + +C p C C C1 1T i M i D i A i, , , ,( )( ) ( )
Scenario 1: nanostructures providingmoreQALYs
We first consider a scenario in which the same quantity
of drug is used in the drug-only treatment (subscript 0)
and the treatment with nanostructures (subscript n/s).
Here, we assume that the use of the nanostructures
improves the quality of life or lifespan of the patient at
increased cost, where quality of life and lifespan are
reflected by the number of QALYs provided, denoted
byQi for treatment i.
This assumption implies that: CT,n/s>CT,0 and
Qn/s>Q0.
Let us define:ΔQ=Qn/s-Q0 andΔC=CT,n/s-CT,0,
where ΔQ is the number of QALYs gained by introdu-
cingDNAnanostructures fordrug-delivery andΔC is the
additional cost.
In the worst-case scenario, the drug-only treat-
ment is just about cost-effective. Here, the cost per
QALY is given by
=C Q C , 2T Q,0 0 ( )/
whereCQ is the threshold cost perQALY.
By definition, the cost per QALY in the nanos-
tructure-enabled case is:
= + D + DC Q C C Q Q 3T n s n s T, ,0 0( ) ( ) ( )/ // /
If the drug-only treatment is only just cost-effective,
andmoving to the nanostructure-treatment is to bemore
cost-effective, we must have CT,n/s/Qn/s<CT,0/Q0.
Table 1.The parameters used in ourmodel.
Parameter Value
p, profitmargin 0.05–0.40 (i.e. 5% to 40%)
cm,DNA, cost permg ofDNAnanostructure Formost of our calculations this wasfixed at £0.15 permg,
except where otherwise stated
mdrug, themass inmg of drug used in a chemotherapy treatment 100–3000 mg
r, themass loading ratio (number ofmg of drug for eachmg ofDNA
nanostructure)
0.01–1
ΔCr&d, total cost of research and development required to bring nanos-
tructure-enabled treatment tomarket
£50million to £4billion
y, the number of years to recoup development costs 1–8 years
t, the number of treatments per year 10 000–200 000
CQ, Threshold cost perQALY £30 000
Cost of drug £0.50/mg to £20/mg
5
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Substitutingusing equation (3) yields:
+ D + D <C C Q Q C QT T,0 0 ,0 0( ) ( )/ /
Rearranging gives:
D < DQ C QCT0 ,0
By substituting using equation (2), we obtain
D > DQ C C 5Q( ) ( )/
We can quantify the right-hand side of this
equation. Using equation (1), we have:
= + + +
= + + +
C p C C C
C p C C C
1
1
T M D A
T n s M n s D n s A n s
,0 ,0 ,0 ,0
, , , ,
( )( )
( )( )/ / / /
As we wish to consider differences in cost between
the nanostructure-enabled and drug-only therapies,
we can ignore any expenditure that would be compar-
able for different approaches. It is reasonable to
assume that the cost of administering the two treat-
ments will be identical, so thatCA,0=CA,n/s.
Thus:
D = -
= + - + -
C C C
p C C C C1
T n s T
M n s M D n s D
, ,0
, ,0 , ,0( )( )
/
/ /
DefiningΔCM as the difference in manufacturing
cost andΔCD as the additional research and develop-
ment cost for the nanostructure-enabled treatment,
we have
D = + D + DC p C C1 6M D( )( ) ( )
ΔCM includes the cost of the materials used to make
the DNA nanostructure, the cost of the labour
involved to make the nanostructure, and the cost of
the labour involved in integrating the drug with the
nanostructure. In most cases the latter will be negli-
gible as drugs could potentially be integrated simply
through incubation of the nanostructures with the
drugs in question. If the cost of manufacturing one
gram of DNA nanostructures (including both parts
and labour) is cm,DNA, the mass of DNA nanostructure
needed for the treatment is mDNA, and the cost of
labour to integrate the drug is omitted, then:
D =C c mM m DNA DNA,
We can express the mass of DNA nanostructure
required in terms of the mass of drug required (mdrug)
and a mass ratio, r. The mass ratio is the number of
grams of drug required for each gram of DNA nanos-
tructure (so r=mdrug/mDNA), and quantifies how
heavily the nanostructure is loaded.Hence:
D =C c m r 7M m DNA drug, ( )/
The additional development costΔCD is the share
of research and development costs to be recouped
from each individual treatment. If ΔCr&d is the total
cost of research and development required to bring the
nanostructure-enabled treatment to market, given
prior approval of the drug-only treatment, andN is the
number of treatments over which cost will be
recouped, then
D = DC C ND r d& /
We can find N by estimating the number of treat-
ments per year (t), and deciding on the number of
years over which development costs must be recouped
(y). Hence:
D = DC C yt 8D r d& ( ) ( )/
Combining equations (6)–(8):
D = + + DC p c m r C yt1
9
m DNA drug r d, &( )(( ) ( ( )))
( )
/ /
This is the additional cost of treating a single
patient with the nanostructure-enabled therapy, as
opposed to the drug-only therapy (figure 1(a)).
Equation (5) specified the condition for which the
cost-effectiveness of the nanostructure-enabled treat-
ment is greater than that of the drug-only treatment,
when the drug-only treatment is only marginally cost-
effective. Combining this with equation (9) gives us
D > + + D
10
Q p c m r C yt C1 m DNA drug r d Q, &
( )
[( )(( ) ( ( )))]/ / /
Most of the parameters on the right-hand side of
equation (10) are variable. We use the range of values
shown in table 1 to evaluate the overall costs.
We find that the costs are particularly high when a
large quantity of drug is needed (figure 1(b)). The
additional cost depends only linearly on the manu-
facturer’s profit margin (figure 1(c)), and the drug
loading ratio is particularly important (figures 1(b),
(c)). When the drug loading ratio is low, the cost is
likely to be high even if the total mass of drug required
is small and the manufacturer accepts low profit mar-
gins. We tested 64 million parameter sets, using 20
evenly spaced values for each of the 6 variables. The
majority of these parameter sets produced nanos-
tructure-enabled therapies that cost less than £20k
more than their drug-only counterparts (figure 1(d)),
but a small number of parameter sets give particularly
high costs.
If £30k is an acceptable cost per QALY, just over
half of the 64million parameter sets describe therapies
that would be cost-effective if they provided less than
0.25 additional QALYs (figure 1(e)). For this calcul-
ation, we assumed that the production cost of DNA
nanostructures was £0.15/mg. This is considerably
cheaper than inorganic nanostructures such as gold
nanoparticles, which are available commercially at
prices of approximately £50/mg. The present cost of
DNA nanostructures for research is much higher
(£200/mg, see Methods), but production volumes are
low. The £0.15/mg value is based on estimates for
synthesis at much larger scales [35], as required for
pharmaceutical production lines. If such low costs
prove to be unachievable, fewer of the parameter sets
will yield cost-effective therapies (figure 1(e), inset).
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For example, if cm,DNA is set at £1.50/mg, only 22% of
the 64 million parameter sets describe therapies that
would be cost-effective if they provided less than 0.25
additional QALYs. If costs of DNA nanostructure pro-
duction remain at present levels, none of the 64 mil-
lion parameter sets describe therapies that would be
cost-effective for a gain of less than 0.7QALYs.
Scenario 2: samenumber ofQALYs, reduced
quantity of drug
We now consider the case in which the number of
QALYs is unchanged but themass of drug is decreased.
Here, money is saved on the drug, but an additional
cost is incurred in manufacturing the nanostructure.
For some combinations of parameters, it will be
Figure 1. Scenario 1: usingDNAnanostructures (‘n/s’) to deliver the drug providesmoreQALYs than the drug-only therapy.
(a)Ourmodel: the equation defining the additional cost for treating one patient with a nanostructured-enabled treatment, over and
above the cost for the drug-only therapy. (b) and (c)Extra costs predicted by themodel when all but two parameters arefixed.
(b)Dependence on themass loading ratio for five different values of themass of drug used for the therapy, with the other parameters
fixed. (c)Dependence on the profitmargin forfive different values of themass loading ratio, with the other parameters fixed.
(d)Histogramof predicted costs for 64million sets of parameter values; the cost ofmanufacturingDNAwas fixed but all other
parameters were variable andwe tested 20 different values for each. (e)Histogram showing the number ofQALYs thatmust be gained
for the situations specified by the parameters in part (d) to be cost effective, for the indicated threshold cost perQALY. Inset: results
obtainedwhen the analysis is repeatedwith greater costs forDNAnanostructure production. Graph shows the fraction of the 64
million parameter sets that give rise to cost-effective therapies for a gain of less than 0.25 additional QALYs (compared to the therapy
without nanostructures).
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cheaper to put the drug in aDNAnanostructure and in
other cases it will be cheaper to use the drug alone. In
scenario 2, the mass of drug used is mdrug
*, and the
mass loading ratio is now r=mdrug
*/mDNA.
The cost of adding the DNA nanostructure as a
drug-delivery vehicle is a modified version of
equation (9):
= + + DC p c m r C yt1add m DNA drug r d, &*( )(( ) ( ( )))/ /
The cost saving due to the decrease in drugmass is
= -S m m cdrug drug drug ,*( )
where cdrug is the cost per unitmass of the drug.
In scenario 2, the net change in cost between the
nanostructure-enabled therapy and the conventional
equivalent (for one patient) is:
D = -
= + + D
- -
C C S













*mdrug. Let us define
mdrug
*=Kmdrug, where 0<K1.Now:
In this scenario, the number of QALYs gained is
the same for both treatments (they are equally effec-
tive). Hence cost-effectiveness is determined simply by
the change in the cost, ΔCs2. If the cost of adding the
nanostructure exceeds the saving incurred by reducing
the amount of drug required, the quantity defined by
equation (11) (figure 2(a)) is positive and the nanos-
tructure-enabled treatment is less cost-effective than
the drug-only approach. The relationship between
mdrug
*, mdrug, mDNA, r and K is depicted graphically in
figure 2(b).
If the introduction of nanostructures enables the
quantity of drug to be reduced by 80%, we find that
55.3% of the parameter sets correspond to situations
in which money is saved, and the nanostructure-
enabled therapy is cheaper (figure 2(c)). We see a
decrease in the proportion of cases in which there is a
net cost saving as the mass of drug increases
(figures 2(d)–(f)). At K=1, the same quantity of drug
is used in the nanostructure-enabled and drug-only
therapies. In this case, by definition, the nanos-
tructure-enabled therapy is less cost-effective than the
drug-only therapy for all possible values of the other
model parameters (figure 2(g)). To elaborate: for
K=1, there is no cost saving on the chemotherapy
agent (as the same amount is used as in the drug-only
case). In addition, significant costs are incurred in
manufacture of the DNA and in development
(through research, testing and clinical trials). The
spread of observed costs arises due to the range of
values for the quantity of nanostructures required, the
profit margin and all the other parameters. As K
decreases, a smaller quantity of drug is required, and
the nanostructures enhance the treatment to a greater
extent.
Hypothetically, if the value of K were to be set
equal to zero, this would imply thatmdrug
*=0. How-
ever, we defined the required quantity of DNA nanos-
tructures with reference to the mass of drug used, and
hence a zero value for mdrug
* implies that the mass of
nanostructures used is also zero. Consequently,K=0
would correspond to a scenario in which development
costs are incurred, but no drug or nanostructure is
administered, and the patient experiences the same
benefit as if taking the drug. This scenario is absurd
and hencewe definedK to be strictly greater than zero.
It is not possible to compute costs for a ‘nanos-
tructure-only’ scenario, because there is no basis on
which to specify the dosage for such a therapy. In any
case, the control experiments in published studies (see
Introduction) suggest that a nanostructure-only treat-
mentwould be entirely ineffective against cancer.
Discussion
In scenario 1, theDNAnanostructures didnot change the
total mass of drug needed to treat the patient but did
increase the number of QALYs provided. This could
correspond to adecrease in side effects, yielding improved
quality of life or more years of life. In this scenario, the
drug-loading ratio was of critical importance, and it will
be essential to optimize this as the technology is
developed.We tested 64million parameter sets, covering
a range of drug loading ratios, total drug mass, profit
margins etc, andwe found that just overhalf of these cases
(51.3%)described therapies thatwould be cost-effective if
they provided less than 0.25 additional QALYs, given that
the cost of DNA nanostructure production was £0.15/
mg.While this is substantially lower than the present cost
ofDNAnanostructures in a research context, it is believed
to be achievable. If major reductions in DNA nanostruc-
ture synthesis cost are not achieved, it is unlikely that
DNA nanostructure-enabled therapies will be cost-
effective. For chemotherapy applications, it will therefore
be essential to demonstrate low-cost manufacture of
DNA nanostructures at scale. As noted by Keller and
Linko [43], this process must comply with the stringent
regulations that apply for biologics and pharmaceuticals,
and this may be particularly challenging in instances
where thenanostructure is basedonagenomic scaffold.
In the second scenario, the number of QALYs pro-
vided was unchanged by the use of DNA nanos-
tructures, but the amount of drug was reduced. If the
reduction was substantial (80%), over half of the para-
meter sets (55.3%) produced a net cost saving,
D = + + D - -C p c Km r C yt m K c1 1 11s m DNA drug r d drug drug2 , &( )(( ) ( ( ))) ( ) ( )/ /
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implying that the nanostructure-enabled therapy
would bemore cost-effective.
In practice, the use of nanostructures to deliver
drugs has the potential to reduce the amount of drug
used and simultaneously increase the number of
QALYs provided, but it would be difficult to model
this scenario with the currently available information.
Our analysis suggests that the use of DNA nanos-
tructures to deliver chemotherapy drugs only needs to
enhance the therapy by a reasonably small amount.
This is a significant result, because it implies that the
technology has the potential to be commercially
viable, if DNA nanostructures can be manufactured
cheaply at scale with appropriate quality. Our method
could also be applied to other early-stage technologies
to assess the likelihood of successful translation as they
becomemoremature.
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therapy but changes the cost by reducing the amount of drug used. (a)Ourmodel: the equation defining the change in the cost for
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*, red) andDNA (mDNA,
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of drug used.K is smaller than or equal to 1 and strictly greater than zero. ForK=1 the use ofDNAnanostructures does not enhance
the potency of the drug and the quantity required is the same as if nanostructures are not used.Note thatmdrug (no asterisk) is themass
of chemotherapy agent used in the drug-only case. (c)–(g)Histograms showing the change in cost for 170,859,375 sets of parameter
values for six different values ofK. The following 7 parameters were variable, and 15 linearly spaced values were tested for each,
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